Other

Idenix Pharmaceuticals, Inc.

Universitá Degli Studi Di Cagliari

Janssen Sciences Ireland Unlimited Company

Janssen Sciences Ireland Uc

Vadim Bichko

Pierre Jean-Marie Bernard Raboisson

Jean-Pierre Sommadossi

Anil Koul

David Francis Alain Lançois

Jérôme Émile Georges Guillemont

Dirk André Emmy Roymans

Antoine Benjamin Michaut

Delphine Yvonne Raymonde Lardeau

David N Standring

Boris Rogovoy

Lin Qu

Alexandre Vasilievich Ivachtchenko

Oleg Dmitrievich Mitkin

Paolo LaColla

Andrey Alexandrovich Ivashchenko

Nikolay Filippovich Savchuk

Alexander Vasilievich Ivashchenko

Paolo La Colla

Sergey Yevgenievich Tkachenko

Vladimir Yurievich Vvedensky

Pavel Mikhailovich Yamanushkin

Jerome Emile Guillemont

David Francis Lancois

Dirk Andre Roymans

Delphine Yvonne Lardeau

Jérôme ÉMile Georges Guillemont

David Francis Alain LANÇOIS

The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. 

RSV antiviral pyrazolo- and triazolo-pyrimidine compounds

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-branched nucleosides and flaviviridae mutation

The present invention relates to novel antiviral active 5-{4-[1H-imidazol-5-ylaryl(or hetaryl)]-buta-1,3-diynyl}-1H-imidazoles of the general formula 1 and pharmaceutically acceptable salt thereof, pharmaceutical composition, antiviral medicament, therapeutic kit for prophylaxis and treatment of hepatisis C virus diseases, and method for prophylaxis and treatment of hepatisis C. wherein:Rand R&#x2014;represent optionally identical radicals selected from 2.1 and 2.2, where an asterisk (*) denotes the position of attachment to the imidazole fragment, (S) and (R) are types of chiral centers; Ris isopropyl or phenyl radicals;Ar an aromatic or heteroaromatic diradical.

Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof

The invention relates to pharmacology and medicine, more particularly to novel pharmaceutical compositions and pharmaceutical kits for treating bacterial infections, and to novel method for treating diseases caused by bacterial infections including tuberculosis. The pharmaceutical composition is disclosed comprising Rifamycin and interferon inducer in pharmacologically effective doses, and also pharmaceutical kit for treating diseases caused by bacterial and healthcare acquired infections, comprising pharmacologically effective doses of Rifamycin in the form of a tablet, a capsule or an injection, interferon inducer in the form of a tablet, a capsule or an injection, and instruction for administration of the components of this pharmaceutical kit.

Pharmaceutical composition and kit for treating bacterial infections

[object Object]

The present invention relates to novel substituted 2-(5-hydroxy-2-methyl-1H-indol-3-yl)acetic acids, to novel antiviral active ingredients, pharmaceutical compositions, antiviral medicaments, methods for prophylaxis and treatment of viral diseases particularly caused by influenza viruses and infectious hepatisis C (HCV) viruses. Novel substituted 2-(5-hydroxy-2-methyl-1H-indol-3-yl)acetic acids, their esters of the general formula 1 and pharmaceutically acceptable salts and/or hydrates thereof have been disclosed wherein: Rrepresents amino group substituent selected from hydrogen, optionally substituted C-Calkyl, acyl or sulfonyl; Rand Rindependently of each other represent alkyl substituent selected from hydrogen, halogen, optionally substituted C-Calkyl, optionally substituted hydroxyl, optionally substituted amino group, optionally substituted aminomethyl, substituted mercapto group; Rrepresents hydrogen, optionally substituted lower C-Calkyl; Rrepresents cyclic system substituent selected from hydrogen, fluorine, trifluoromethyl, carboxy group, alkyloxycarbonyl, possibly substituted aryl, heterocyclyl, optionally substituted aminomethyl, cyano group; Rrepresents hydroxyl group substituent selected from hydrogen, optionally substituted C-Calkyl, acyl.

Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from seine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (Sequence ID No. 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-branched nucleosides and Flaviviridae mutation

Growing community of inventors

San Diego, CA, United States of America

Vadim Bichko